Methods of treating gastrointestinal stromal tumors

A method of treating a human patient suffering from an advanced gastrointestinal stromal tumor, comprising:

• orally administering to the human patient a 150 mg daily dose of ripretinib, wherein the patient has previously been administered at least three or more separate tyrosine kinase inhibitors wherein one of the at least three or more separate tyrosine kinase inhibitors is imatinib, and two of the separate tyrosine kinase inhibitors are selected from the group consisting of sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatalanib, crenolanib, and pharmaceutically acceptable salts thereof;
• and
• wherein the human patient achieves 6 months of progression free survival, as determined by mRECIST 1.1, after at least 28 days of the daily ripretinib administration.